17 related articles for article (PubMed ID: 1403059)
1. The effects of Suramin on Ca
Williams DW; Stephenson DG; Posterino GS
Physiol Rep; 2017 Jul; 5(14):. PubMed ID: 28743820
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.
Zandvliet AS; Schellens JH; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2008; 47(8):487-513. PubMed ID: 18611060
[TBL] [Abstract][Full Text] [Related]
3. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant.
Prager D; Li HL; Asa S; Melmed S
Proc Natl Acad Sci U S A; 1994 Mar; 91(6):2181-5. PubMed ID: 8134369
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
[TBL] [Abstract][Full Text] [Related]
5. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
[TBL] [Abstract][Full Text] [Related]
7. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
[TBL] [Abstract][Full Text] [Related]
8. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
[TBL] [Abstract][Full Text] [Related]
9. Suramin: rapid loading and weekly maintenance regimens for cancer patients.
van Rijswijk RE; van Loenen AC; Wagstaff J; Meijer E; Lopez R; van Groeningen CJ; Heimans JJ; Pinedo HM
J Clin Oncol; 1992 Nov; 10(11):1788-94. PubMed ID: 1403059
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]